129 related articles for article (PubMed ID: 35841761)
1. World-wide trends in net survival from pancreatic cancer by morphological sub-type: An analysis of 1,258,329 adults diagnosed in 58 countries during 2000-2014 (CONCORD-3).
Nikšić M; Matz M; Valkov M; Marcos-Gragera R; Stiller C; Rosso S; Coleman MP; Allemani C;
Cancer Epidemiol; 2022 Oct; 80():102196. PubMed ID: 35841761
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. Worldwide trends in esophageal cancer survival, by sub-site, morphology, and sex: an analysis of 696,974 adults diagnosed in 60 countries during 2000-2014 (CONCORD-3).
Matz M; Valkov M; Šekerija M; Luttman S; Caldarella A; Coleman MP; Allemani C;
Cancer Commun (Lond); 2023 Sep; 43(9):963-980. PubMed ID: 37488785
[TBL] [Abstract][Full Text] [Related]
4. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.
Allemani C; Matsuda T; Di Carlo V; Harewood R; Matz M; Nikšić M; Bonaventure A; Valkov M; Johnson CJ; Estève J; Ogunbiyi OJ; Azevedo E Silva G; Chen WQ; Eser S; Engholm G; Stiller CA; Monnereau A; Woods RR; Visser O; Lim GH; Aitken J; Weir HK; Coleman MP;
Lancet; 2018 Mar; 391(10125):1023-1075. PubMed ID: 29395269
[TBL] [Abstract][Full Text] [Related]
5. Incidence and relative survival of pancreatic adenocarcinoma and pancreatic neuroendocrine neoplasms in Germany, 2009-2018. An in-depth analysis of two population-based cancer registries.
Stang A; Wellmann I; Holleczek B; Fell B; Terner S; Lutz MP; Kajüter H
Cancer Epidemiol; 2022 Aug; 79():102204. PubMed ID: 35777306
[TBL] [Abstract][Full Text] [Related]
6. Does the morphology of cutaneous melanoma help to explain the international differences in survival? Results from 1 578 482 adults diagnosed during 2000-2014 in 59 countries (CONCORD-3).
Di Carlo V; Stiller CA; Eisemann N; Bordoni A; Matz M; Curado MP; Daubisse-Marliac L; Valkov M; Bulliard JL; Morrison D; Johnson C; Girardi F; Marcos-Gragera R; Šekerija M; Larønningen S; Sirri E; Coleman MP; Allemani C;
Br J Dermatol; 2022 Sep; 187(3):364-380. PubMed ID: 35347700
[TBL] [Abstract][Full Text] [Related]
7. Worldwide trends in population-based survival for children, adolescents, and young adults diagnosed with leukaemia, by subtype, during 2000-14 (CONCORD-3): analysis of individual data from 258 cancer registries in 61 countries.
Ssenyonga N; Stiller C; Nakata K; Shalkow J; Redmond S; Bulliard JL; Girardi F; Fowler C; Marcos-Gragera R; Bonaventure A; Saint-Jacques N; Minicozzi P; De P; Rodríguez-Barranco M; Larønningen S; Di Carlo V; Mägi M; Valkov M; Seppä K; Wyn Huws D; Coleman MP; Allemani C;
Lancet Child Adolesc Health; 2022 Jun; 6(6):409-431. PubMed ID: 35468327
[TBL] [Abstract][Full Text] [Related]
8. Italian cancer figures, report 2012: Cancer in children and adolescents.
; ;
Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
[TBL] [Abstract][Full Text] [Related]
9. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2).
Matz M; Coleman MP; Carreira H; Salmerón D; Chirlaque MD; Allemani C;
Gynecol Oncol; 2017 Feb; 144(2):396-404. PubMed ID: 27919574
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
11. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres.
Frizziero M; Wang X; Chakrabarty B; Childs A; Luong TV; Walter T; Khan MS; Morgan M; Christian A; Elshafie M; Shah T; Minicozzi A; Mansoor W; Meyer T; Lamarca A; Hubner RA; Valle JW; McNamara MG
World J Gastroenterol; 2019 Oct; 25(39):5991-6005. PubMed ID: 31660035
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of gastroenteropancreatic neuroendocrine tumours.
Fraenkel M; Kim MK; Faggiano A; Valk GD
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):691-703. PubMed ID: 23582913
[TBL] [Abstract][Full Text] [Related]
14. Non-functional pancreatic neuroendocrine tumours: emerging trends in incidence and mortality.
Wu J; Sun C; Li E; Wang J; He X; Yuan R; Yi C; Liao W; Wu L
BMC Cancer; 2019 Apr; 19(1):334. PubMed ID: 30961556
[TBL] [Abstract][Full Text] [Related]
15. Cancer survival in five continents: a worldwide population-based study (CONCORD).
Coleman MP; Quaresma M; Berrino F; Lutz JM; De Angelis R; Capocaccia R; Baili P; Rachet B; Gatta G; Hakulinen T; Micheli A; Sant M; Weir HK; Elwood JM; Tsukuma H; Koifman S; E Silva GA; Francisci S; Santaquilani M; Verdecchia A; Storm HH; Young JL;
Lancet Oncol; 2008 Aug; 9(8):730-56. PubMed ID: 18639491
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
17. Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas.
Ryschich E; Huszty G; Knaebel HP; Hartel M; Büchler MW; Schmidt J
Eur J Cancer; 2004 Jun; 40(9):1418-22. PubMed ID: 15177502
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 - 2015.
Koizumi T; Otsuki K; Tanaka Y; Kanda S
BMC Endocr Disord; 2022 Apr; 22(1):105. PubMed ID: 35443668
[TBL] [Abstract][Full Text] [Related]
19. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
20. Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective.
Pinto MP; Muñoz Medel M; Carrillo D; Retamal IN; Bravo ML; Valenzuela Y; Nervi B; Sánchez C; Galindo H; Ibañez C; Peña J; Balmaceda C; Madrid J; Briones J; Torres J; Nilo F; Guarda FJ; Quintana JC; Orellana P; Mondaca S; Acevedo F; Vicentini D; Cordova-Delgado M; Owen GI; Garrido M
Horm Cancer; 2019 Feb; 10(1):3-10. PubMed ID: 30465145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
